Healthcare services group Uniphar said today that it remains confident of delivering on its earnings expectations for the year.
In a trading update for the six months to the end of June, Uniphar said the business performed in line with its expectations at both a gross profit and EBITDA level.
It said this represents another strong period of performance, demonstrating the resilience of the business.
Uniphar continues to maintain a strong liquidity position and continues to review an active pipeline of acquisition opportunities, it added.
"The group continues to maintain a disciplined approach to capital allocation while managing an active pipeline of acquisition opportunities across all divisions and a number of geographies to further enhance the group's growth potential," the company said.
Uniphar reported organic gross profit growth of over 5%, driven by organic growth across each division and continued outperformance in Supply Chain & Retail.
It added that the integration of the McCauley Pharmacy Group, bought in January 2023, is progressing in line with expectations.
Ger Rabbette, Uniphar group chief executive said, the company performed well during the six month period, delivering strong organic gross profit growth.
"The resilience of our business model and the diversity of our product offering has once again been demonstrated with each division delivering organic growth in gross profit during the period," the CEO said.
"We also continue to invest across all of our platforms to ensure continued, robust growth in 2023 and beyond," he stated.
"Having delivered on our strategic objective of doubling EBITDA within five years of IPO, we will communicate new medium-term targets with our interim results," he added.
Shares in the company were lower in Dublin trade today.
